Sanofi is stepping up its presence in India and emerging markets, one of the Group’s growth platform
Sanofi in India
Chief Executive Officer, Christopher A. Viehbacher’s visit to India this month offered an opportunity to reaffirm the importance of emerging markets as a Sanofi growth platform. The Group’s presence in India was strengthened in August by an agreement with Universal Medicare, due to be completed in the fourth quarter of 2011, and the 2009 acquisition of Shantha Biotechnics.
Good news for Shantha
Shantha Biotechnics develops and produces high-quality vaccines at affordable prices for international markets. The World Health organization, has just pre-qualifies Shanchol, a vaccine against cholera that UN agencies will make available for the poorest countries. Cholera is a severe diarrheal disease that can kill within hours if it is not treated. There are an estimated 3 to 5 million cases annually worldwide, resulting in 100,000 to 120,000 deaths.
Extended offer for the patients
The agreement with Universal Medicare signed in August 2011 - due to be finalized during Q4 of this year - focuses on nutraceuticals (such as antioxidants, vitamins, and mineral supplements). It would facilitate the creation of a consumer healthcare and wellness platform and would extend the offering to the Indian population.
- India has a population of about 1.2 billion.
- The Indian market will be the eighth largest in the world in 2015 (1)
- The pharmaceutical market grew by 17.6% in 2010
- Sanofi has had a presence in India since 1956
- It is the second largest multinational in terms of growth (2)
- Sanofi employs approximately 3,700 people in its four entities
(Aventis Pharma Ltd., Sanofi-Synthelabo (India) Ltd., Sanofi Pasteur Private Ltd, Shantha Biotechnics Ltd)
(1) IMS market outlook 2011-2015 market ranking in constant US$
(2) IMS MIDAS MAT Q1 2011